Low-molecular-weight heparins: Pharmacoeconomic decision modeling based on meta-analysis data

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 3, 2010, Pages 272-279

  Kadusevicius, Edmundas ^a,b   Kildonaviciute, Gabriele ^a,c   Varanaviciene, Birute ^b   Jankauskiene, Danguole ^d  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^b KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^c IQVIA   (United States)

^d MYKOLAS ROMERIS UNIVERSITY   (Lithuania)

Author keywords

Cost minimization; Low molecular weight heparins (LMWHs); Meta analysis; Reference pricing; Unfractionated heparin (UFH)

Indexed keywords

CONFIDENCE INTERVAL; COST MINIMIZATION; DECISION MODELING; DECISION MODELS; END POINTS; FIXED EFFECTS; HEALTHCARE INSTITUTIONS; LITHUANIA; LOW-MOLECULAR WEIGHT HEPARINS; META-ANALYSIS; ODDS RATIOS; RANDOM EFFECTS; RANDOMIZED CONTROL TRIALS; REFERENCE PRICING; RESEARCH OBJECTIVES; UNFRACTIONATED HEPARINS;

COST BENEFIT ANALYSIS; DATA HANDLING; OPTIMIZATION; POLYSACCHARIDES;

COSTS;

DALTEPARIN; ENOXAPARIN; HEPARIN; NADROPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; LITHUANIA; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; DECISION SUPPORT SYSTEM; ECONOMICS; PHARMACOECONOMICS;

DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS;

EID: 78049434942     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310000310     Document Type: Article

References (57)

1. Aaserud M, Dahlgren AT, Kösters JP, et al. Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Syst Rev. 2006;2:CD005979.
2. Agnelli G, Piovella F, Buoncristiani P. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med. 1998;339:80-85.
3. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.NEngl JMed. 2006 Apr 6;354(14):1477-88. Epub 2006 Mar 14.
4. Arenas-Guzman R, Tosti A, Hay R, et al. National Institute for Clinical Excellence. Pharmacoeconomics-an aid to better decision-making. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):34-39.
5. Belcaro G, Nicolaides AN, Cesarone MR, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology. 1999 Oct;50(10):781-7.
6. Bounameaux H, Huber O, Khabiri E, et al. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg. 1993 Mar;128(3):326-8.
7. Bozovich GE, Gurfinkel EP, Antman EM, et al. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J. 2000 Oct;140(4):637-42.
8. Burotto M, Gabrielli L, Crossley N. Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164: 1077-83.
9. Chiou-Tan FY, Garza H, Chan KT, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patientswith spinal cord injury.AmJ PhysMed Rehabil. 2003 Sep;82(9):678-85.
10. Chong BH, Brighton TA, Baker RI, et al. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis. 2005 Jun;19(3):173-81.
11. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol. 2003 Oct 15;42(8):1348-56.
12. Cohen M, Theroux P, Borzak S, et al. Randomized doubleblind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J. 2002 Sep;144(3):470-7.
13. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop Relat Res. 1995 Dec;(321):19-27.
14. de Lemos JA, Blazing MA, Wiviott SD, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: Results from the A phase of the A-to-Z trial. Eur Heart J. 2004 Oct;25(19):1688-94.
15. Egger B, Schmid SW, Naef M, et al. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients. Dig Surg. 2000;17(6):602-609.
16. Engberg S. Systemic review andmeta-analysis: Studies of studies. J Wound Ostomy Continence Nurs. 2008;35:258-265.
17. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997 Aug;84(8):1099-103.
18. Findik S, Erkan ML, Selcuk MB, et al. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration. 2002;69(5):440-4.
19. Fitchett DH, Langer A, Armstrong PW, Tan M, et al. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J. 2006 Feb;151(2):373-9.
20. Godoy I, Herrera C, Zapata C, et al. Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina. Rev Med Chil. 1998 Mar;126(3):259-64.
21. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-QWave Coronary Events; J AmColl Cardiol. 2000 Sep;36(3):693-8.
22. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators., Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide; Circulation. 2003 Jan 21;107(2):238-44.
23. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B., Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia; J Am Coll Cardiol. 1995 Aug;26(2):313-8.
24. Guyton AC, Hall JE. Textbook of medical physiology. Elsevier: Saunders; 2006:464.
25. HafeliR,Kraljevic S,WehrliC,Goede J, ConenD., Lowmolecular weight heparin (dalteparin) in treatment of patients with thromboembolism incidents; Praxis (Bern 1994). 2001 Aug 16;90(33):1339-45.
26. Hartl P, Brucke P, Dienstl E, et al. Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and Fragmin; Thromb Res. 1990 Feb 15;57(4): 577-84.
27. Hoffman MJ, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures - 2004. Am J Health Syst Pharm. 2004 February.
28. HolmstromM,Aberg W, LocknerD, PaulC. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: A retrospective analysis. Thromb Haemost. 1999 Oct;82(4):1222-6.
29. Hong YJ, Jeong MH, Lee SH, et al. The use of low molecular weight heparin to predict clinical outcome in patients with unstable angina that had undergone percutaneous coronary intervention. Korean J Intern Med. 2003 Sep;18(3):167-73.
30. Klein W, Buchwald A, Hillis SE, et al. Comparison of lowmolecular- weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation. 1997 Jul 1;96(1):61-8.
31. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous lowmolecular- weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996 Mar 14;334(11):682-7.
32. Lindmarker P, HolmstromM,Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis; Thromb Haemost. 1994 Aug;72(2):186-90.
33. Luomanmaki K, Grankvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med. 1996 Aug;240(2):85-92.
34. Madan M, Radhakrishnan S, Reis M, et al. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). Am J Cardiol. 2005 Jun 1;95(11):1295-301.
35. Malhotra S, Karan RS, Bhargava VK, et al. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina. Indian Heart J. 2001;53:197-202.
36. Miraldo M. Reference pricing and firms pricing strategies. J Health Econ. 2009;28:176-197.
37. Montalescot G, Bal-dit-Sollier C, Chibedi D, et al. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol. 2003 Apr 15;91(8):925-30.
38. Moreno-Palomares JJ, Fisac-Herrero RM, Herrero-Domingo A, et al. Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis. An Med Interna. 2001 Jul;18(7):364-8.
39. Ngorsuraches S. Defining types of economic evaluation. J Med Assoc Thai. 2008;91(Suppl 2):S21-S27.
40. Official website of Kaunas Medical University Hospital. www.kmuK.lt (accessed on August 17, 2009).
41. Okmen E, Ozen E, Uyarel H, et al. Effects of enoxaparin and nadroparin onmajor cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor. Jpn Heart J. 2003 Nov; 44(6):899-906.
42. Ozdemir M, Erdem G, Turkoglu S, et al. Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: A single center experience. Jpn Heart J. 2002 Sep;43(5):433-42.
43. Richter A. Assessing the impact of global price interdependencies. Pharmacoeconomics. 2008;26:649-659.
44. Ross AM,Molhoek P, Lundergan C, et al.Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001 Aug 7;104(6):648-52.
45. Shafiq N, Malhotra S, Pandhi P, et al. A Randomized Controlled Clinical Trial to Evaluate the Efficacy, Safety, Cost- Effectiveness and Effect on PAI-1 Levels of the Three Low- Molecular-Weight Heparins - Enoxaparin, Nadroparin and Dalteparin. Pharmacology 2006;78:136-143.
46. Simonneau G, Laporte S, Mismetti P, et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006 Aug;4(8):1693-700. Epub 2006 Jun 21.
47. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med. 1997 Sep 4;337(10):663-9.
48. Sirenko IuN, SychevOS, ReikoMN, et al.The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology. Klin Khir. 1994;(12):23-5.
49. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: Prophylaxis with low-dose heparin or enoxaparin. J Trauma. 2003 Jun;54(6):1111-5.
50. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: A randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. J Trauma. 2003 Jun;54(6):1116-24; discussion 1125-6.
51. Sprague S, Quigley L, Adili A, et al. Understanding cost effectiveness: Money matters? J Long Term Eff Med Implants. 2007;17:145-152.
52. Stargardt T, Schreyögg J, Busse R. Pharmaceutical reference pricing in Germany: Definition of therapeutic groups, price setting through regression procedure and effects. Gesundheitswesen. 2005;67:468-477.
53. Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: A randomized pilot trial comparing low molecular weight heparin to unfractionated heparin; J Obstet Gynaecol Can. Aug;26(8):729-34.
54. The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 1998 Nov;75(11):1058-63.
55. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999 Nov;20(21):1553-62.
56. Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-theASSENT Plus study. Eur Heart J. 2003 May;24(10):897-908.
57. Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Aust N Z J Obstet Gynaecol. 1998 Feb;38(1): 91-2.